EP3285754A1 — Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
Assigned to TWi Biotechnology Inc · Expires 2018-02-28 · 8y expired
What this patent protects
A controlled-release formulation containing diacerein or its analogs is provided. Also provided is a method of lowering blood levels of uric acid using this formulation. In one embodiment, the invention provides a controlled-release formulation with reduced adverse side effects a…
USPTO Abstract
A controlled-release formulation containing diacerein or its analogs is provided. Also provided is a method of lowering blood levels of uric acid using this formulation. In one embodiment, the invention provides a controlled-release formulation with reduced adverse side effects and/or higher bioavailability, comprising an immediate-release layer and an extended-release layer.
Drugs covered by this patent
- Uloric (FEBUXOSTAT) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.